secwatch.observer — SEC 8-K summary
======================================

Issuer:     ProMIS Neurosciences Inc. (PMN)
CIK:        0001374339
Form:       8-K
Filed at:   2024-11-14T23:59:59+00:00
Accession:  0001558370-24-015632
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ProMIS Q3 net income $9.3M, cash $21.5M; Phase 1a positive; PIPE up to $122.7M
------------------------------------------------------------------------------

- Net income of $9.3M for Q3 2024 vs net loss of $2.4M YoY, driven by $17.0M gain on warrant liabilities.
- Cash and equivalents $21.5M at Sep 30, 2024, up from $12.6M at Dec 31, 2023.
- PIPE financing closed with initial $30.3M; potential additional $92.4M from warrant exercise.
- Phase 1a trial of PMN310 in Alzheimer's showed good tolerability, dose-dependent BBB crossing, supporting monthly dosing.
- Phase 1b clinical trial in AD patients on track to start by end of 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1374339/000155837024015632/0001558370-24-015632-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1374339/000155837024015632/pmn-20241114x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-015632

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer